Lisinopril

Hazard statements (CLP)

H360D, H373

Code

Statements

H360D

May damage the unborn child

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Reproductive toxicity, (Category H360D: May damage the unborn child. 1A) Specific target organ toxicity - H373: May cause damage to organs repeated exposure, (Category 2), through prolonged or repeated exposure. Kidney

Signal word

Danger Danger

Hazard statements

H360D May damage the unborn child. H373 May cause damage to organs (Kidney) through prolonged or repeated exposure. H360D May damage the unborn child.

Precautionary statements

P202 Do not handle until all safety precautions have been read and understood. P260 Do not breathe dust/ fume/ gas/ mist/ vapors/ spray. P280 Wear protective gloves/ protective clothing/ eye protection/ face protection. P308 + P313 IF exposed or concerned: Get medical advice/ attention. P405 Store locked up. P501 Dispose of contents/ container to an approved waste disposal plant. P202 Do not handle until all safety precautions have been read and understood. P280 Wear protective gloves/ protective clothing/ eye protection/ face protection. P308 + P313 IF exposed or concerned: Get medical advice/ attention. P405 Store locked up. P501 Dispose of contents/ container to an approved waste disposal plant.

Supplemental label elements

none Reduced Labeling (<= 125 ml) none

Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher

ECOLOGICAL INFORMATION

The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

TOXICOLOGICAL INFORMATION

The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.